News

Tyrosine-kinase inhibitors (TKIs) are a mainstay of therapy for patients with advanced thyroid cancer, more than doubling progression-free survival. Unfortunately, their use is limited not only by gastrointestinal adverse events (AEs), such as diarrhea and anorexia, but also by significant weight loss, which has been reported in 10% to 50% of patients treated with TKI therapies.

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients, according to results of a new study, the first to examine long-term outcomes of patients with low- versus intermediate-risk prostate cancer who have been managed with this conservative approach to care.

The Multiple Myeloma Research Foundation provides educational programs to help people with myeloma, family members, caregivers, and healthcare professionals learn more about the disease and today's most promising treatment options, including clinical trials, from leading multiple myeloma doctors and researchers.

This section provides you with brief background information about kidney cancer and some immediate resources that may be helpful.